NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

RecruitingPhase 3

Sponsor: Axsome Therapeutics, Inc.

Conditions: Smoking Cessation

Interventions: AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo

Countries: United States

This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female, aged 18 to 65 (inclusive)

Exclusion Criteria:

* Unable to comply with study procedures.
* Medically inappropriate for study participation in the opinion of the investigator.

Locations (9)

Little Rock, Arkansas, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Stockbridge, Georgia, United States
Kansas City, Missouri, United States
Brooklyn, New York, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Newport News, Virginia, United States